CEL-SCI Corporation
8229 Boone Boulevard
Suite 802
Vienna,
VA 22182
United States - Map
Phone: 703-506-9460
Fax: 703-506-9471
Website: http://www.cel-sci.com
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The companys principal product, Multikine, is under Phase III clinical trial for the treatment of head and neck cancer. The Multikine is an immunotherapeutic agent consisting of a mixture of cytokines that produce an anti-tumor immune response. It also develops Ligand Epitope Antigen Presentation System (LEAPs), a heteroconjugate technology that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, develops a peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia. Key Statistics
| |
| | Pay | Exercised | Mr. Maximilian De Clara ,
83
Founder, Chairman and Pres | 465.00K | 0.00 | Mr. Geert R. Kersten Esq.,
54
Chief Exec. Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer and Director | 534.00K | 0.00 | Ms. Patricia B. Prichep ,
62
Sr. VP of Operations and Corp. Sec. | 216.00K | 0.00 | Dr. Eyal Talor Ph.D.,
57
Chief Scientific Officer | 265.00K | 0.00 | Dr. Daniel H. Zimmerman Ph.D.,
72
Sr. VP of Cellular Immunology | 205.00K | 0.00 |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.00(0.40%) May 24, 4:00PM EDT